Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schmidt, N; Grammer, T; Gouni-Berthold, I; Julius, U; Kassner, U; Klose, G; König, C; Laufs, U; Otte, B; Steinhagen-Thiessen, E; Wanner, C; März, W.
CaRe high - Cascade screening and registry for high cholesterol in Germany.
Atheroscler Suppl. 2017; 30(1):72-76
Doi: 10.1016/j.atherosclerosissup.2017.05.015
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. To improve FH diagnosis in the general population a cascade screening and registry data is warranted, yet missing in Germany. This project aims to fill this gap. Study assistants approach physicians and lipid clinics to introduce the cascade screening and registry. The physicians identify potential FH patients and include them in the study. Patient data is acquired via questionnaires about medical history. Patients meeting at least two inclusion criteria (LDL-C >190 mg/dl or total cholesterol >290 mg/dl; tendon xanthomas; family history of hypercholesterolemia or early myocardial infarction) are included in the registry. Family members will be contacted and physicians get feedback about diagnosis and treatment options. Ethical approvals for all German states have been collected. So far physicians, lipid clinics and patients within the Rhein-Neckar region, the Saarland, North-Rhine-Westphalia, Upper Bavaria, Bremen, Saxonia and Berlin have joined the study. We expect to include more than 3000 patients during the next two years. After initial patient and data collection the project aims to improve FH-diagnosis and treatment. Utilizing registry data might advance diagnostic criteria and improve detection of FH and thus prevent CVD in this population. Copyright © 2017. Published by Elsevier B.V.
- Find related publications in this database (using NLM MeSH Indexing)
- Biomarkers - blood
- Cholesterol, LDL - blood
- Genetic Markers -
- Genetic Predisposition to Disease -
- Genetic Testing - methods
- Germany -
- Humans -
- Hyperlipoproteinemia Type II - blood
- Hyperlipoproteinemia Type II - diagnosis
- Hyperlipoproteinemia Type II - genetics
- Hyperlipoproteinemia Type II - therapy
- Lipid Metabolism - genetics
- Mutation -
- Patient Selection -
- Phenotype -
- Predictive Value of Tests -
- Prognosis -
- Program Evaluation -
- Registries -
- Risk Factors -
- Find related publications in this database (Keywords)
- Familial hypercholesterolemia
- Cascade screening
- Patient registry
- Cardiovascular disease